Executive Order 14292: Improving the Safety and Security of Biological Research

What does Executive Order 14292 do?

The text directs Funding agencies to pause prohibited or concerning research, and OSTP and agencies to replace oversight and screening policies.

Reading the operative provisions of Executive Order 14292

EO 14292 pauses specified federally funded research that the administration classifies as dangerous gain-of-function research and directs agencies to create replacement oversight policies. It also addresses foreign research funding and nucleic-acid screening. The order’s assignments are set out in the Federal Register text of EO 14292. It operates through federal funding and agency oversight; it is not a general criminal prohibition on every privately funded biological experiment.

Gain-of-function is a broad scientific term, and the order uses a defined policy scope for the research it covers. Agencies must identify affected awards, communicate funding conditions and determine whether work can proceed under any exception. A pause on federal support can alter project timelines, but it does not itself resolve a scientific question about risk or benefit. Researchers and institutions need the actual agency notice and grant terms to know what work is restricted.

The order also calls for oversight of certain research performed abroad with federal support and screening of synthetic nucleic-acid orders. Those issues involve different mechanisms: grant conditions, institutional review, vendor screening and federal reporting. Any replacement framework must specify covered experiments, risk review, exceptions and accountability. A public-health or security goal does not remove the need for clear standards and fair grant administration. Implementation can be tracked through agency guidance, award decisions and published oversight rules.